Submission Details
| 510(k) Number | K253743 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | November 24, 2025 |
| Decision Date | March 12, 2026 |
| Days to Decision | 108 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
K253743 is an FDA 510(k) clearance for the MiniMed Flex pump, a Alternate Controller Enabled Insulin Infusion Pump (Class II — Special Controls, product code QFG), submitted by Medtronic Minimed, Inc. (Northridge, US). The FDA issued a Cleared decision on March 12, 2026, 108 days after receiving the submission on November 24, 2025. This device falls under the Chemistry review panel. Regulated under 21 CFR 880.5730.
| 510(k) Number | K253743 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | November 24, 2025 |
| Decision Date | March 12, 2026 |
| Days to Decision | 108 days |
| Submission Type | Traditional |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
| Product Code | QFG — Alternate Controller Enabled Insulin Infusion Pump |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 880.5730 |
| Definition | An Alternate Controller Enabled Insulin Infusion Pump (ace Insulin Pump) Is A Device Intended For The Infusion Of Insulin Into A Patient. The Ace Insulin Pump May Include Basal And Bolus Drug Delivery At Set Or Variable Rates. Ace Insulin Pumps Are Designed To Reliably And Securely Communicate With External Devices, Such As Automated Insulin Dosing Systems, To Allow Insulin Delivery Commands To Be Received, Executed, And Confirmed. Ace Insulin Pumps Are Intended To Be Used Both Alone And In Conjunction With Digitally Connected Medical Devices For The Purpose Of Insulin Delivery. |